LU92782I2 - Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson - Google Patents

Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson Download PDF

Info

Publication number: LU92782I2
Authority: LU; Luxembourg
Prior art keywords: safinamide; levodopa; pdi; parkinson; drugs
Prior art date: 2003-04-11

Application number

LU92782C

Other languages

English (en)

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2015-07-22

Publication date

2015-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92782(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-22 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2015-09-22 Publication of LU92782I2 publication Critical patent/LU92782I2/fr

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229960004502 levodopa Drugs 0.000 title 1
NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 title 1
229950002652 safinamide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU92782C 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson LU92782I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11

Publications (1)

Publication Number	Publication Date
LU92782I2 true LU92782I2 (fr)	2015-09-22

Family

ID=33159845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92782C LU92782I2 (fr)	2003-04-11	2015-07-22	Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson

Country Status (28)

Country	Link
US (3)	US8283380B2 (fr)
EP (2)	EP1613296B1 (fr)
JP (2)	JP2006522800A (fr)
KR (2)	KR101129015B1 (fr)
CN (2)	CN1771030A (fr)
AR (1)	AR044007A1 (fr)
AT (1)	ATE435012T1 (fr)
AU (1)	AU2004228782B2 (fr)
BR (1)	BRPI0409364A (fr)
CA (1)	CA2523188C (fr)
CY (3)	CY1109295T1 (fr)
DE (1)	DE602004021790D1 (fr)
DK (2)	DK2070526T3 (fr)
ES (2)	ES2326373T3 (fr)
FR (1)	FR15C0054I2 (fr)
HU (1)	HUS1500043I1 (fr)
IL (2)	IL171331A (fr)
LU (1)	LU92782I2 (fr)
MX (1)	MXPA05010873A (fr)
NL (1)	NL300752I2 (fr)
NO (3)	NO334316B1 (fr)
NZ (1)	NZ542910A (fr)
PL (2)	PL2070526T3 (fr)
PT (2)	PT2070526E (fr)
RU (1)	RU2342929C2 (fr)
SI (2)	SI2070526T1 (fr)
TW (1)	TWI340640B (fr)
WO (1)	WO2004089353A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
CN1274306C (zh)	2001-09-03	2006-09-13	纽朗制药有限公司	包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
EP1438956A1 (fr) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Dérivés alpha-aminoamides en tant qu'agents antimigraine
US20070276046A1 (en) *	2003-08-25	2007-11-29	Patricia Salvati	Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1588704A1 (fr)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
RS51411B (sr) *	2004-09-10	2011-02-28	Newron Pharmaceuticals S.P.A.	Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
US8772346B2 (en)	2005-11-09	2014-07-08	Torrent Pharmaceuticals Limited	Pharmaceutical composition
IN266803B (fr)	2005-12-22	2015-06-03	Newron Pharm Spa
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (fr) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
KR101491541B1 (ko)	2006-06-19	2015-02-09	뉴론 파마슈티칼즈 에스. 피. 에이.	2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
EP2150239A1 (fr) *	2007-04-24	2010-02-10	Boehringer Ingelheim International GmbH	Combinaison comprenant une préparation de comprimés à libération prolongée, contenant du pramipexole ou un de ses sels pharmaceutiquement acceptable
TR201802576T4 (tr) *	2007-06-15	2018-03-21	Newron Pharm Spa	Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
US20090149544A1 (en) *	2007-10-22	2009-06-11	Concert Pharmaceuticals, Inc.	Alpha-aminoamide derivatives
EP3257842B1 (fr)	2007-12-11	2020-11-18	Newron Pharmaceuticals S.p.A.	Utilisation thérapeutique de 2-[4-(3- ou 2-fluorobenzyloxy) benzylamino] propanamides de grande pureté
CN101903021B (zh) *	2007-12-19	2012-11-14	纽朗制药有限公司	用于治疗精神病的α-氨基酰胺衍生物
US20110027354A1 (en) *	2008-04-01	2011-02-03	Kim Hyoung-Chun	Anti-parkinsonian compounds
PL2285769T3 (pl)	2008-06-02	2015-01-30	Generics Uk Ltd	Sposób otrzymywania enancjomerycznie czystych amin
AU2009254929B2 (en) *	2008-06-02	2014-03-13	Generics [Uk] Limited	An improved process for the preparation of amines
RU2540470C9 (ru) *	2008-06-06	2015-07-20	Фарма Ту Б Лтд.	Фармацевтические композиции для лечения болезни паркинсона
EP2296462A4 (fr) *	2008-06-13	2011-06-15	Teva Pharma	Administration de rasagiline à des fins de modification de l'évolution de la maladie de parkinson
WO2010010138A1 (fr) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Composition pharmaceutique renfermant du pramipexole et un inhibiteur des canaux calciques pour le traitement de la maladie de parkinson
US20100189790A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
EP2218444A3 (fr) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Formulation de rasagiline à libération retardée
EP2314569A1 (fr)	2009-10-22	2011-04-27	Merck Patent GmbH	Nouvelles formules polymorphiques de sel de mesylate (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide, et son procédé de fabrication
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (fr)	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide dans le traitement de la dyskinésie
LT2563355T (lt)	2010-04-27	2016-09-26	Newron Pharmaceuticals S.P.A.	Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas
JP5820469B2 (ja)	2010-04-30	2015-11-24	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダンの経皮組成物
EP2688561B1 (fr)	2011-03-24	2018-08-22	Teikoku Pharma USA, Inc.	Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
WO2013028639A1 (fr)	2011-08-19	2013-02-28	The Trustees Of Princeton University	Formation de liaison c-halogène
EP2776020B1 (fr)	2011-11-09	2019-09-11	Teikoku Seiyaku Co., Ltd.	Méthodes pour le traitement de tumeurs de la peau
RU2685718C2 (ru)	2012-10-22	2019-04-23	Сивитас Терапьютикс, Инк.	Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP6050896B2 (ja)	2012-11-02	2016-12-21	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダン経皮組成物
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
US10111879B2 (en)	2013-06-27	2018-10-30	Cedars-Sinai Medical Center	Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN106659685B (zh) *	2014-04-21	2021-02-05	丝维塔斯治疗公司	快速减轻帕金森病中的运动波动
WO2016052928A1 (fr) *	2014-10-02	2016-04-07	한국과학기술연구원	Composé dérivé d'alpha-aminoamide et composition pharmaceutique le comprenant
KR20180041234A (ko) *	2015-08-27	2018-04-23	프렉스톤 테라퓨틱스 에스에이	레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체
KR102889062B1 (ko) *	2016-03-17	2025-11-21	더 존스 홉킨스 유니버시티	Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (fr) *	2017-01-14	2020-12-09	Neurrx, SPC	Procédé d'utilisation d'excréments et de sécrétions humains pour la détection précoce de la maladie de parkinson
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
CA3072994A1 (fr) *	2017-08-17	2019-02-21	Zi-Qiang Gu	Agents anti-parkinson de type sels de pamoate de monoamine, leur procede de preparation et d'utilisation
CA3080975A1 (fr)	2017-11-02	2019-05-09	Zambon S.P.A.	Compositions pharmaceutiques comprenant du safinamide
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
DK4027815T5 (en) *	2019-09-12	2026-08-03	Achieve Life Sciences Inc	Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
US20230028539A1 (en) *	2019-12-06	2023-01-26	Shanghai Pharmaceuticals Holding Co., Ltd.	Pharmaceutical composition, complementary kit and application thereof
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (fr) *	2020-08-31	2022-03-03	Purdue Pharma L.P.	Compositions et méthodes d'administration de lévodopa
KR20230154249A (ko) *	2021-03-08	2023-11-07	프로테나 바이오사이언시즈 리미티드	파킨슨 질환의 치료
KR102790040B1 (ko) *	2021-06-24	2025-04-01	연세대학교 산학협력단	도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제
CN117615768A (zh) *	2021-06-24	2024-02-27	韦斯特兰德特斯创新股份公司	用于帕金森病的nad增效疗法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
DE3779500T2 (de) *	1986-06-10	1993-01-21	Chiesi Farma Spa	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
CA1336169C (fr)	1988-03-01	1995-07-04	Walther Birkmayer	Agent utilise dans le traitement de la maladie de parkinson
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DK0828513T3 (da) *	1995-05-26	2004-04-13	Pfizer	Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9515412D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 EP EP04726590A patent/EP1613296B1/fr not_active Expired - Lifetime
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/fr not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 CA CA2523188A patent/CA2523188C/fr not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/fr not_active Ceased
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/fr unknown
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL216403A (en)	2015-01-29
SI1613296T1 (sl)	2009-10-31
AU2004228782A1 (en)	2004-10-21
CY1109295T1 (el)	2014-07-02
CA2523188C (fr)	2012-09-25
FR15C0054I1 (fr)	2015-11-09
CN102274517B (zh)	2018-08-31
NO20054640D0 (no)	2005-10-10
NZ542910A (en)	2007-10-26
IL216403A0 (en)	2011-12-29
US20150150833A1 (en)	2015-06-04
AR044007A1 (es)	2005-08-24
KR20060010745A (ko)	2006-02-02
RU2005131422A (ru)	2006-04-27
JP2013067647A (ja)	2013-04-18
ES2454272T3 (es)	2014-04-10
CN1771030A (zh)	2006-05-10
NO20131417L (no)	2005-12-09
EP1613296A2 (fr)	2006-01-11
CY2015025I1 (el)	2016-04-13
PL1613296T3 (pl)	2009-12-31
WO2004089353A2 (fr)	2004-10-21
DK1613296T3 (da)	2009-10-05
NO2015018I1 (no)	2015-08-03
WO2004089353A8 (fr)	2005-09-01
RU2342929C2 (ru)	2009-01-10
US9492410B2 (en)	2016-11-15
PT2070526E (pt)	2014-03-31
HUS1500043I1 (hu)	2018-11-28
US20130053368A1 (en)	2013-02-28
KR20110070929A (ko)	2011-06-24
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
WO2004089353A3 (fr)	2004-12-16
PT1613296E (pt)	2009-07-30
NO2015018I2 (no)	2015-07-23
PL2070526T3 (pl)	2014-08-29
IL171331A (en)	2012-03-29
JP2006522800A (ja)	2006-10-05
NO334316B1 (no)	2014-02-03
TW200505423A (en)	2005-02-16
CA2523188A1 (fr)	2004-10-21
TWI340640B (en)	2011-04-21
FR15C0054I2 (fr)	2018-01-26
AU2004228782B2 (en)	2010-05-20
BRPI0409364A (pt)	2006-04-25
US8283380B2 (en)	2012-10-09
CY1115286T1 (el)	2017-01-04
DE602004021790D1 (de)	2009-08-13
US8901176B2 (en)	2014-12-02
DK2070526T3 (da)	2014-03-24
EP2070526B1 (fr)	2014-02-26
ES2326373T3 (es)	2009-10-08
CN102274517A (zh)	2011-12-14
ATE435012T1 (de)	2009-07-15
EP1613296B1 (fr)	2009-07-01
NL300752I2 (fr)	2016-07-05
KR101129015B1 (ko)	2012-04-20
MXPA05010873A (es)	2006-03-21
NO335537B1 (no)	2014-12-22
EP2070526A1 (fr)	2009-06-17
SI2070526T1 (sl)	2014-05-30
CY2015025I2 (el)	2016-04-13

Publication	Publication Date	Title
NO2015018I1 (no)	2015-08-03	Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom
PT1446122E (pt)	2006-08-31	Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
EP1727567A4 (fr)	2010-10-13	Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies a un complement
WO2005034998A3 (fr)	2005-08-11	Procedes et compositions destines au traitement de la douleur et d'autres etats a mediation adrenergique alpha-2
EP1850880A4 (fr)	2010-09-22	Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
WO2004069146A3 (fr)	2006-09-28	Derives d'amide l-dopa et utilisations de ceux-ci
IL190150A0 (en)	2008-08-07	New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
EP1676512A3 (fr)	2008-12-10	Articles pour traitement de la peau et méthodes
HRP20130602T1 (en)	2013-07-31	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP2035412A4 (fr)	2011-02-16	Agonistes du récepteur muscarinique convenant au traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
MA29084B1 (fr)	2007-12-03	Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
IL177787A0 (en)	2006-12-31	1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
FR2886851B1 (fr)	2007-10-05	Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
DZ3141A1 (fr)	2001-01-14	Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
FR2866340B1 (fr)	2006-11-24	Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
IL185300A0 (en)	2008-02-09	New pharmaceutical compositions useful in the treatment of parkinson's disease
BRPI0811538A2 (pt)	2015-08-11	Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
PL378360A1 (pl)	2006-03-20	Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju
MA28343A1 (fr)	2006-12-01	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
ITRM20050446A1 (it)	2007-02-20	Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
WO2008042314A3 (fr)	2008-10-09	Diagnostic et traitement de troubles de l'oeil
EP2272497A3 (fr)	2011-03-23	Procédés pour augmenter la fonction lymphatique
EP2137156A4 (fr)	2011-06-22	Promédicaments biodisponibles par voie orale de (+)-3-hydroxymorphinane utilisés dans la prévention ou le traitement de la maladie de parkinson
WO2006012521A3 (fr)	2006-05-04	Traitement de maladies oculaires